GSK

Equity

GSK plc

Health Care · Drug Manufacturers - General

$59.13

+59.13 (+0.00%)

Open

N/A

Day Range

$58.33 - $59.36

52W Range

$32.38 - $61.70

Volume

6M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires 2 days ago

GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments

Proactive 2 days ago

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

GlobeNewswire 2 days ago

GSK Strikes $1 Billion China RNA Deal

GuruFocus.com 3 days ago

SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Zacks 3 days ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ABUS Arbutus Biopharma Corporation $4.66 N/A - +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

www.gsk.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

55

Borderline

Based on 4 fundamental factors

~ Recent dividend growth (2 yr)

Analysis Tools

Sign in for analysis tools

Share